Pharmacogenomics in prevention of diabetic cardiovascular disease: utilization of the haptoglobin genotype in determining benefit from vitamin E.

Pharmacogenomics in prevention of diabetic cardiovascular disease: utilization of the haptoglobin genotype in determining benefit from vitamin E. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Pharmacogenomics in prevention of diabetic cardiovascular disease: utilization of the haptoglobin genotype in determining benefit from vitamin E. Abstract Text:

Andrew P Levy,Shany Blum,Andrew P Levy,Shany Blum,

Numerous large clinical trials have been carried out over the past several years testing the ability of the antioxidant vitamin E to prevent diabetic cardiovascular disease. Meta-analysis of these studies has demonstrated that vitamin E does not provide any cardiovascular protection and may be associated with an increase in mortality. However, these studies did not address possible benefit to subgroups with increased oxidative stress. In this review we provide supporting clinical evidence and a mechanistic basis for utilizing a genetic marker, the haptoglobin genotype, in determining whether vitamin E therapy may or may not be beneficial for a given patient with diabetes.

Pharmacogenomics in prevention of diabetic cardiovascular disease: utilization of the haptoglobin genotype in determining benefit from vitamin E. Publishing Authors By Initials

AP Levy,S Blum,AP Levy,S Blum,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Pharmacogenomics in prevention of diabetic cardiovascular disease: utilization of the haptoglobin genotype in determining benefit from vitamin E. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Expert review of cardiovascular therapy

VOLUME: 5

Page Numbers: 1105-11

Journal Abbreviation:

ISSN: 1744-8344

DAY: 26

MONTH: Nov

YEAR: 2007

Pharmacogenomics in prevention of diabetic cardiovascular disease: utilization of the haptoglobin genotype in determining benefit from vitamin E. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101182328

Pharmacogenomics in prevention of diabetic cardiovascular disease: utilization of the haptoglobin genotype in determining benefit from vitamin E. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Pharmacogenomics in prevention of diabetic cardiovascular disease: utilization of the haptoglobin genotype in determining benefit from vitamin E. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Pharmacogenomics in prevention of diabetic cardiovascular disease: utilization of the haptoglobin genotype in determining benefit from vitamin E.

AFFILIATION: Technion-Israel Institute of Technology, Department of Cell Biology and Anatomy, Technion Faculty of Medicine, PO Box 9649, Haifa, Israel. alevy@tx.technion.ac.il

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Expert Rev Cardiovasc Ther

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Pharmacogenomics in prevention of diabetic cardiovascular disease: utilization of the haptoglobin genotype in determining benefit from vitamin E Related Publications

• Attenuation of actinomyosinII contractile activity in growth cones accelerates filopodia-guided and microtubule-based neurite elongation.
• Autophagy in MHC class II antigen processing.
• Biochips: non-conventional strategies for biosensing elements immobilization.
• Characterization of side effects sustained by chiropractic students during their undergraduate training in technique class at a chiropractic college: a preliminary retrospective study.
• Citicoline is not protective in experimental models of Huntington's disease.
• Congenital toxoplasmosis from an HIV-infected woman as a result of reactivation.
• Effects of vitamin E on fowl semen storage at 4 degrees C.
• Entrapment neuropathy of the ulnar nerve by a constriction band: the role of MRI.
• Feeding a diet containing a fructooligosaccharide mix can enhance salmonella vaccine efficacy in mice.
• Hepatitis C virus infection and apoptosis.
• Hepatitis C virus infection: in vivo and in vitro models.
• Homocysteine (Hcy) follow-up study.
• Lack of Minocycline Efficiency in Genetic Models of Huntington's Disease.
• Nuclear receptor and nuclear receptor target gene messenger ribonucleic acid levels at different sites of the gastrointestinal tract and in liver of healthy dogs.
• Papulonodular mucinosis in a child with systemic lupus erythematosus.
• Peripherally acting opioid antagonists in the treatment of opiate-related constipation: a systematic review.
• Pharmacogenomics in prevention of diabetic cardiovascular disease: utilization of the haptoglobin genotype in determining benefit from vitamin E.
• Postprandial blood hormone and metabolite concentrations influenced by feeding frequency and feeding level in veal calves.
• Sampling properties of homozygosity-based statistics for linkage disequilibrium.
• School food practices of prospective teachers.
• Suppression of immune responses in collagen-induced arthritis by a rationally designed CD80-binding peptide agent.
• SynopSIS: integrating physician sign-out with the electronic medical record.
• Treatment of painful peripheral neuroma by vein implantation.
• [Effects of minimal doses estrogens derived from natural substances on vaginal absorption, with a contribution on the therapy of leukorrhea.]
• [From skin to pluripotent stem cells: reprogramming of adult somatic cells.]
• [Mechanisms of neuronal death in Huntington's disease. First part: general considerations and histopathological features]
• [Percutaneous liver biopsy]
• [Regional therapy of liver tumors]
• [Technical considerations for injection of a mixture of iodinated contrast material and Artirem for combined CT and MR arthrography]
• [The hepatocellular carcinoma: alternative therapeutical strategies]